European Journal of Medicinal Chemistry p. 48 - 61 (2019)
Update date:2022-09-26
Topics:
Li, Yuanyuan
Zhang, Silong
Zhang, Jing
Hu, Zhiye
Xiao, Yuan
Huang, Jian
Dong, Chune
Huang, Shengtang
Zhou, Hai-Bing
As the mutant estrogen receptor (ER) continues to be characterized, breast cancer is becoming increasingly difficult to cure when treated with hormone therapy. In this regard, a strategy to selectively and effectively degrade the ER might be an effective alternative to endocrine therapy for breast cancer. In a previous study, we identified a novel series of 7-oxabicyclo[2.2.1]heptene sulfonamide (OBHSA) compounds as full ER antagonists while lacking the prototypical ligand side chain that has been widely used to induce antagonism of ERα. Further crystal structure studies and phenotypic assays revealed that these compounds are selective estrogen receptor degraders (SERDs) with a new mechanism of action. However, from a drug discovery point of view, there still is room to improve the potency of these OBHSA compounds. In this study, we have developed new classes of SERDs that contain the OBHSA core structure and different side chains, e.g., basic side chains, long alkyl acid side chains, and glycerol ether side chains, to simply mimic the degrons of proteolysis targeting chimera (PROTAC) and then investigated the structure-activity relationships of these PROTAC-like hybrid compounds. These novel SERDs could effectively inhibit MCF-7 cell proliferation and demonstrated good ERα degradation efficacy. Among the SERDs, compounds 17d, 17e and 17g containing a basic side chain with a N-trifluoroethyl substituent and a para methoxyl group at the phenyl group of the sulfonamide turned out to be the best candidates for ER degraders. A further docking study of these compounds with ERα elucidates their structure-activity relationships, which provides guidance to design new PROTAC degrons targeting ER for breast cancer therapy. Lastly, easy modification of these PROTAC-like SERDs enables further fine-tuning of their pharmacokinetic properties, including oral availability.
View MoreShanghai Sungo Technology Chemical Co., Ltd
Contact:0086-21-51385579
Address:Room2010, F/20, Tonghua Plaza, NO 345 Jinxiang Road, Jinqiao Export Processing Zone, Shanghai, 201206 P.R.CHINA
Contact:86-27-84888681
Address:Wuhan economic & technology development zone
Shanghai better-in Medical Technology Co.,LTD.
Contact:+86-21-38921049
Address:Lane 720 zhangjianggaoke cailun road, Pudong, Shanghai, room 513
Shanghai Forever Biotech Co., Ltd.
Contact:+86-21-69734790
Address:Room 5017/5019、5022、5024 of Technology Innovation Centre, No.1155, Gongyuan East Rd, QingPu District, Shanghai China.
Contact:+86-25-52346955
Address:199,JIANYE ROAD,NANJING,CHINA
Doi:10.1016/j.bmcl.2012.09.093
(2012)Doi:10.1021/ja00035a039
(1992)Doi:10.1016/j.ejmech.2017.03.088
(2017)Doi:10.1246/cl.1992.535
(1992)Doi:10.2174/157017812803521081
(2012)Doi:10.1246/cl.2011.1456
(2011)